Lichenoid drug eruption secondary to topical timolol and dorzolamide eye-drops

Australasian Journal of Dermatology

Volumn 45, Issue 2, 2004, Pages 151-152

  Mullins, Raymond J ^a   Lones, Robert ^a   Dutta, Bish ^b  

^a John James Medical Centre   (Australia)

^b Dr Bish Dutta   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BRIMONIDINE; DORZOLAMIDE; EYE DROPS; LATANOPROST; TIMOLOL; TIMOLOL MALEATE;

AGED; CASE REPORT; DRUG ERUPTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; GLAUCOMA; HUMAN; IMMUNE RESPONSE; INFLAMMATION; LETTER; LICHENOID ERUPTION; MALE; PATHOGENESIS; RASH; SKIN BIOPSY;

ADRENERGIC BETA-ANTAGONISTS; AGED; ANTIHYPERTENSIVE AGENTS; DRUG ERUPTIONS; GLAUCOMA; HUMANS; LEG DERMATOSES; LICHENOID ERUPTIONS; MALE; OPHTHALMIC SOLUTIONS; SULFONAMIDES; THIOPHENES; TIMOLOL;

EID: 2342548698     PISSN: 00048380     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-0960.2004.00074.x     Document Type: Letter

References (16)

1. El-Serag HB, Hampel H, Yeh C, Rabeneck L. Extrahepatic manifestations of hepatitis C among United States male veterans. Hepatology 2002; 36: 1439-45.
2. Petrou-Amerikanou C, Markopoulos AK, Belazi M, Karamitsos D, Papanayotou P. Prevalence of oral lichen planus in diabetes mellitus according to the type of diabetes. Oral Dis. 1998; 4: 37-40.
3. Marshman G. Lichen planus. Australas. J. Dermatol. 1998; 39: 1-11.
4. Shiohara T. The lichenoid tissue reaction. Am. J. Dermatol. 1988; 10: 252-6.
5. Halevy S & Shai A. Lichenoid drug eruptions. J. Am. Acad. Dermatol. 1993; 29: 249-55.
6. Seehafer JR, Rogers RS III, Fleming CR, Dickson ER. Lichenplanus-like lesions caused by penicillamine in primary biliary cirrhosis. Arch. Dermatol. 1981; 117: 140-2.
7. Beckman KA, Chanes L, Kaufman SR. Lichen planus associated with topical beta-blocker therapy. Am. J. Ophthalmol. 1985; 120: 530-1.
8. Hodl S. Side effects of beta receptor blockers on the skin. Review and personal observations. Hautarzt 1985; 36: 549-57.
9. Hodl S. Side-effects of beta-receptor blockaders on the skin. Z Hautkr. 1983; 58: 17-28.
10. Anonymous. Cutaneous reactions to labetalol. BMJ 1978; 15: 987.
11. Sitenga GL, Ing EB, Van Dellen RG, Younge BR, Leavitt JA. Asthma caused by topical application of ketorolac. Ophthalmology 1996; 103: 890-2.
12. Bauer KG, Brunner-Ferber F, Distlerath LM, Lippa EA, Binkowitz B, Till P, Kaik GA. Assessment of bronchial effects following topical administration of butylamino-phenoxy-propanol-acetate, an oculoselective beta-adrenoceptor blocker in asthmatic subjects. Br. J. Clin. Pharmacol. 1992; 34: 122-9.
13. Odeh M, Oliven A, Bassan H. Timolol eyedrop-induced fatal bronchospasm in an asthmatic patient. J. Fam. Pract. 1991; 32: 97-8.
14. Delaney YM, Salmon JF, Mossa F, Gee B, Beehne K, Powell S. Periorbital dermatitis as a side effect of topical dorzolamide. Br. J. Ophthalmol. 2002; 86: 378-80.
15. Taguri AH, Khan MA, Sanders R. Marginal keratitis: an uncommon form of topical dorzolamide allergy. Am. J. Ophthalmol. 2000; 130: 120-2.
16. Halevy S, Grunwald MH, Sandbank M, Buimovice B, Joshua H, Livni E. Macrophage migration inhibition factor (MIF) in drug eruption. Arch. Dermatol. 1990; 126: 48-51.